Entrada Therapeutics Inc - Asset Resilience Ratio
Entrada Therapeutics Inc (TRDA) has an Asset Resilience Ratio of 41.40% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Entrada Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Entrada Therapeutics Inc's Asset Resilience Ratio has changed over time. See Entrada Therapeutics Inc (TRDA) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Entrada Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TRDA total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $123.72 Million | 41.4% |
| Total Liquid Assets | $123.72 Million | 41.40% |
Asset Resilience Insights
- Very High Liquidity: Entrada Therapeutics Inc maintains exceptional liquid asset reserves at 41.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Entrada Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Entrada Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Seegene Inc
KQ:096530 |
Biotechnology | 24.96% |
Annual Asset Resilience Ratio for Entrada Therapeutics Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Entrada Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 54.40% | $205.30 Million | $377.38 Million | -6.17pp |
| 2024-12-31 | 60.57% | $318.79 Million | $526.32 Million | -0.04pp |
| 2023-12-31 | 60.61% | $284.37 Million | $469.19 Million | +3.65pp |
| 2022-12-31 | 56.95% | $143.56 Million | $252.06 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $305.83 Million | -- |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potent… Read more